Cover Image

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand 177Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.

Saved in:
Bibliographic Details
Main Authors: Delker, Andreas (Author) , Fendler, Wolfgang Peter (Author) , Kratochwil, Clemens (Author) , Brunegraf, Anika (Author) , Gosewisch, Astrid (Author) , Gildehaus, Franz Josef (Author) , Tritschler, Stefan (Author) , Stief, Christian Georg (Author) , Kopka, Klaus (Author) , Haberkorn, Uwe (Author) , Bartenstein, Peter (Author) , Böning, Guido (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: European journal of nuclear medicine and molecular imaging
Year: 2015, Volume: 43, Issue: 1, Pages: 42-51
ISSN:1619-7089
DOI:10.1007/s00259-015-3174-7
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-015-3174-7
Get full text
Author Notes:Andreas Delker, Wolfgang Peter Fendler, Clemens Kratochwil, Anika Brunegraf, Astrid Gosewisch, Franz Josef Gildehaus, Stefan Tritschler, Christian Georg Stief, Klaus Kopka, Uwe Haberkorn, Peter Bartenstein and Guido Böning
Description
Summary:Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand 177Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.
Item Description:Gesehen am 07.05.2020
Physical Description:Online Resource
ISSN:1619-7089
DOI:10.1007/s00259-015-3174-7

Similar Items